NGX-267

N/A

Report date: 2026/04/18 20:00:19
NME

Base Information

Drug NameNGX-267
Drug Alias NameAF-267BNGX-267NSC-001NI-004
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor M1 agonistsAmyloid beta-protein precursor inhibitors
TargetsMuscarinic acetylcholine receptor M1Amyloid beta-protein precursor
Therapy Area/IndicationsAlzheimer DiseaseXerostomiaSjogren's Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustriaGermany
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHorizon PharmaLife Science Research Israel Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNeuroscios GmbhNSC-Therapeutics GmbHNeurimmune Ag
Inactive CompaniesTorreypines Therapeutics Inc
Active IndicationsAlzheimer Disease
Inactive IndicationsXerostomiaSjogren's Syndrome

Other Information

ATC CodeN/A
Related LinksDrugBank